Business
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts. Abstracts are now available online and can be accessed within the AAN annual meeting program at www.aan.com/msa/public/events/index/45. Details of the presentations are outlined below. Poster Presentation Title: Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs Presentation Date/Time: Tuesday, April 25, 8:00am – 9:00am ETSession: P7: MS Therapeutics 1Abstract Number/Poster Number: 3185/011 in Neighborhood 3Lead Author: DeRen Huang, MD, PhD, Columbus Neuroscience, Westerville, OH Poster Presentation Title: Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies Presentation Date/Time: Monday, April 24, 5:30pm – 6:30pm ETSession: P6: MS Clinical TrialsAbstract Number/Poster Number: 3199/015 in Neighborhood 3Lead Author: Lawrence Steinman, MD, Stanford University, Stanford, CA Poster Presentation Title: Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis Presentation Date/Time: Monday, April 24, 5:30pm – 6:30pm ETSession: P6: MS Clinical TrialsAbstract Number/Poster Number: 3092/002 in Neighborhood 3Lead Author: Enrique Alvarez, MD, PhD, University of Colorado, Aurora, CO Following the presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm. ABOUT THE ULTIMATE I & II PHASE 3 TRIALSULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered i...